Title

Rituximab in immunologic glomerular diseases

Authors

Authors

A. A. Ejaz; A. Asmar; M. M. Alsabbagh;N. Ahsan

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

mAbs

Keywords

rituximab; glomerular diseases; transplant; rejection; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IDIOPATHIC MEMBRANOUS NEPHROPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTIBODY-ASSOCIATED VASCULITIS; DEPENDENT NEPHROTIC SYNDROME; PROLIFERATIVE LUPUS NEPHRITIS; CHRONIC; LYMPHOCYTIC-LEUKEMIA; ANCA-ASSOCIATED VASCULITIS; B-CELL DEPLETION; RENAL-TRANSPLANTATION; Medicine, Research & Experimental

Abstract

Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.

Journal Title

Mabs

Volume

4

Issue/Number

2

Publication Date

1-1-2013

Document Type

Review

Language

English

First Page

198

Last Page

207

WOS Identifier

WOS:000303594200003

ISSN

1942-0862

Share

COinS